US regulators require GLP-1 makers to warn of rare optic nerve condition
- US regulators require eye-condition warnings on GLP-1 drugs.
- NAION can cause sudden, lasting vision loss.
- The link remains uncertain; patients should consult their doctor.
The US Food and Drug Administration has ordered makers of popular GLP-1 medicines to add warnings about NAION, a rare eye condition that can cause sudden, potentially permanent vision loss. The decision follows a review that found an increased risk of rare cases among people taking the drugs,…